Antiarrhythmic efficacy by a class III agent with and without betablockade in chronic atrial fibrillation — a double-blind randomized comparison of DI-sotalol, D-sotalol and placebo  by Edvardsson, Nils et al.
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<.t. I-'5 6,,-t0 11--15 16-20 
No, Gm~ 61t 1206 t039 480 1~2 
Pa~em (%) (73) (73) (68) (62) (60) 
NO. Grafts 14 38 78 77 ~18 
S:enosad (.,~) (1.7) (2.3) (4,9) (s.g) : (19) _ 
FlOW < 40 mVmin predicted early graft fagum in 397 graft. Fa i r s  lrom 
Cox analysis most ixedicU~ of long-term lower graft !~toncy were: ir,:mas- 
ing no. grafts p~aced (RR 1.43), Y graft toch~ (RR 1.3), diabetes (RR 
1.23), smotdng (RR t.15) and grafts to d i~ artelies (RR 1.61). Choles- 
terol, •glycedde, HOL-Cltolesteml levels were not pfedictom. I~de ~ex (RR 
0.78), surgery for LV aneulysm (RR 0.23) and grafts to LAD (RR t.34) were 
Wed~ of ~a~r gra I~e~'/. 
Thus mmidanm of large numbem of gratts~ Y g~ te~niques, cigarette 
,mo~ng, emd cam~ (~ml  of ~abeteS shau~ enhar~ ~g-torm g~ 
pammy. 
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[ ~  Anttarrh~l~mi¢ Efficacy by a Agent Class III W,h 
end Without BetaMockade in Chronk: Atrial 
FibdllMIon ~ A Double.Blind Randomized 
Co .~ l tm ot 01.Sotalol, O.Sotalol ~1 Placebo 
Nils Edvardsso. ~, Heik~ Hu~k~, G~lan Ke~el~k, 
T ~ ,  Be~gt Ullmon, for a Eu~opea~ MuIlicenter SkJ~y, 
d , ~  (DL) is a dass III a r ~  dn.~l wlth betabic~.er (BB] e~ecls. 
TI~ placebo (PLA) compads~ betweefl Ok ertd i~ dex!~isomer d-s~d~l 
(D), which is devokJ Of dink~ BB a~i~y, lUOvided a t~ique ~ to 
eye.ale lhe f lwra l~ value Of the BB in DL 34g palkmls (pat) with dlmnic 
md~ f ib~a~ (N:) wm ind.dad after rml~l malnta~r~l st.us d~thm 
(SR) fro" > 2 h followi~ ~uscessful DC o0mversk~ Pat ~ ~ to 
w~h DL 80 mg BID (118 I~t), D 1()0 mg BID (t17 pa~) m PLA (114 
pat). "the d~me was cU)ul~d ee~er one week and me i~  fo, owed at vfs~s 
a.d ~ t~epho~ ECG ~ 6 mo~s In SR or . ,~  m~se. ~ were 
37 pal (',]12%) remained in 5R allm" 6 moths on PLA, remus 59 pat (50%) 
on OL (p,, 0.(~e) and 47 pat (40%) on D (NS). The d i l~  between DL 
and 0 ImJvJw Ioward ~_  _~,~aJ s~m~ance, p ~ 0.059. The ~ tinm to 
~ ~Io AF w~, longm no OL,. 167 days vm,r, us 15 days o~I O and 14 
0uy~ oe P,_,, (p - 0.~3). ~ lwse  ~e~s mm more o0rnm~ m DL (e0%) 
Ne  oe O (4~) mJ PLA (43%) and were rela~ to tha BB. The heart nee 
e~ , -~e  ~ m O emd PLA Ixe not DL. Tlmm was no pr0ante/tlm~ 
m ,~¢~,o~ 0L was ~ecUve in keq~g mm I. SR a,d in delay~g me 
line Io ndap~ wNie O was n~4 ~ morn ele~Jve than PLA. The 
mdy =o~rmwd ~ eCe~vmess ~'~d s~fety of 0L and ~kx.memd, (or the 
rm ume. ~,e ~ln~ar~ uwalx,,uc ~ of ~ BS in AF. 
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.............. Mahttmmllm~ of 9~us  Rh~ In P l tbn~ W~h Mrkd 
tu t t i6 .13pL  ~ ~. ;  Qmme rail 10mt~ In 24 i~  ~ I~  
v~l~k:ulw e~l~n ka¢llm v~B 0~ a: 0.13. S cfole ms ~-480 n~/4 as 
10crams ~ A ~ m leOO ml~l ~ s~ ~ 400 me, d ~ 1 nvx~ 
~q~u~ ~ ,  m ~ S mJ ~2 mum~ A. Tl~m ~a no 
1 ~ r ~  ~ m , m ~  Sm ~r S pare  em ~0~r + ~ m~ 
~ emue e~qu~ ~ m m dmmm m m ~ ~ A. ~ n~t  ~. .~ 
follow-,p, only 6/25 pts assigned to .~ remain on S: in contrast, 17/'25 pts 
assigned to A remain on A (p < 0.01). Age. duration of AF. left atrial size. 
and the l:~mnce of I~  v~lar  hypertr0phy. ~uc~und heart disease, and 
impaired venfficUlar h, lc~on f~u'led to pr~ AF recUnence i ~  Of 
asS~ed ~rnen~ 
Co~/~:ws: Low-dose A is more elfe~lve 1ban S in wevenUng AF mcur- 
mr¢~ in pts who have previou~ failed class I agents. In this study, ~l~lical 
vedables failed to i~xediof ~ AF. 
11:00 
Amiocisrone Is More Effective Then Placebo for 
Spontaneous Restoration and Malnteusnve of Sinus 
Rhythm in Patkmts With Chronic ArUal Fibrillation 
and Congestive H~_rt Fe~llure 
Prakash C. D~m'wania, B ~  N, Singh, KennelJ1 Ellenbogen, 
Steven $ingh, Ross Flelcher, Susan Fisher, for Ihe CHF-~TAT 
Invesligators. VACSP and VAMG-Fmsno. CA; UCSF School Of Medicine. 
8an Frands~, CA 
AMal ltbdlla~on (A*flb) is a common anhy~mla which is difficult o mange 
in par i s  (pts) with CHF because of the adverse e~ects Of most anl~. 
rh~ dn~s. Although an~0dar0ne (A) has been used in A-fib, ~ttvely 
li l~ infomlalion is; ~aJlable from plgspe(~Jve placebo conlrolled ~ n~ 
galt~g its use in pts wig1 CHF and A.fib. We compmed the elfectS of A 
versus placebo (P) on A-fib in 667 pts ~ d]b~l can~omyopathy, s stolic 
dysfunction (mean LVEF 25%), CHR and venfficula~ anhythmi~ (PVCs > 
10/h) who palli~pa~ed in the VA 8tm,,tval Trial of Aofianhythmi~ Therapy 
in CHF (CHF-STA'T). Of the 667 ~ pts. 330 w~m randomized.to A and 
337 to P, A was given w~ a Ioeding drJ~e of 800 mg qd for 14 days, lhen 
400 mg qd for I year, and then 300 n~g qd unlfl the end of tha sludy. All 
pts were followed at 3-too tnlervaL9 when 12 lead EKGs were oblained and 
24.hr Ho~" moniloflng wa~ performed at 1, 3, 6, 9, 12 mo~ mid Uq~m every 
6 mus fer the dural~n oflhe study, At baseline a tc~al of 103 tots (51 in A 
and 52 in P group) had A-fib. During the 4.5 yrs folicwup 16 (31%) of I1~ 51 
pts randomized to A had spontaneously ~nvem~ to and maintained sinus 
zhythm (:ompamd to only 4 (~F~,) of the ,$2 A-f~b pto on P (X 2 = 12.9, P= 
0.005). Because pts with CHF f ~  develop new A-fib, we eval,mt__~ 
lira dsk Ot .ew A4~ in tho~ with sinus ~hylhn~ Si~ificangy (X~ = 9.2, P = 
0.002) fower (n = 11,4%) patients on A developed new A-fit) compared with 
th0~ on P (n = ~2, 8%). 
C.or~us~n: A is ~ betler than P in restoring and maintaining 
sinus rhythm in p~ents with CHF and A-lib. 
11:15 
in Patients With and Wilhout Structural Heart 
Bsease 
~ ~u~,  S~ano D~a Ca~ Wa~ ~k~n~, Mar~ Samuel ,  
e.mo MagnonL ~etute Of ~ u , /~ ,~ ~e~,~.  
The e~cacy and safety ot ixmafe.ono (PFN) as s~gle oraJ k~ l  dose 
~, ~ reo~-o.s~ ~r~ mml~on (AF) (_< 7 ~ays d.raeon) tosVw 
dlytl~ (SR) veem evalu,~ed In a placebo-coofmg~ study. Afl~ 2 hours Of 
~ o~ervaUon. 240 hr~ '~ paee ~-:~ LoU). NYHA ~ms <_ 2. wtemut 
m Of hemt ~ were rando~ allo~ed to ~,amwmt with PFN (600 mo 
as s~e oraJ ~e)  ~ ~ (PLA) (~n0 Ho~er .x~.  ~n ~e vd~e 
popUis~ PFN rusultod ~ more elfec~e than PLA in remdng 
SR ~ a~ 3 houn; (54/119 pts = 45% vs 22/121 pis = 18%, p < 0,001) 
or at 8 houm (91/,19 p~ ,. 7~ vs 45/121 pts = 37%, p < 0.001). Ana l~ 
Of ~ sutquq~ showed for Pm ~ ellcacy ,~i,~&-~ 8 hours Of 78% 
~nees~e Ptm), aria d SW. (a;n~) u pu w~ saueur~ he~t c,~eaue 
0m). "n~ cenemmding ,gum ~ PLA were: ~ ,  ~ )  ~ NoHD p~ 
27% (10r~ in Hyp pls, and 17% (5/30) in HD pts (p < 0.01 vs NOHD). No 
smmm m~me eflects im ~ ellects: i~ases of sustai~ 
uu',al ~ or tacS~ae~ were omaved .~ 7 pu on PLA (I case of ~:1 
AV ¢m~uc~ at 240 brn) and In 8 im .n PRM ~ rm ~ 150 
kinking aow i~ ;.~;V e~m ~ O Imm In mmm~,~ AF. even ~n m 
~ HO ~ a ~ sa~y ~ On ~ ~ tmn~ c ,~n~m to 
